Enterprise Value
195.5M
Cash
119.8M
Avg Qtr Burn
-18.48M
Short % of Float
11.42%
Insider Ownership
2.58%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATI-1777 (JAK 1/3 inhibitor) Details Atopic dermatitis, Skin disease/disorder | Phase 2b Data readout | |
Zunsemetinib (ATI-450) (MK2 inhibitor) Details Psoriatic arthritis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2a Data readout | |
ATI-2138 (ITK/JAK3 inhibitor) Details Autoimmune disease, Ulcerative colitis | Phase 2a Initiation | |
ATI-2231 (MK2 inhibitor) Details Solid tumor/s, Pancreatic cancer, Cancer, Metastatic breast cancer | Phase 1a Initiation | |
Zunsemetinib (ATI-450) Details COVID-19 | Failed Discontinued | |
Zunsemetinib (ATI-450) (MK2 inhibitor) Details Hidradenitis suppurativa | Failed Discontinued | |
Zunsemetinib (ATI-450) Details Rheumatoid arthritis | Failed Discontinued |